Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Cash (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Change in Cash data on record, last reported at -$4.2 million in Q4 2025.

  • For Q4 2025, Change in Cash rose 93.37% year-over-year to -$4.2 million; the TTM value through Dec 2025 reached -$28.7 million, down 65.43%, while the annual FY2025 figure was -$28.7 million, 65.43% down from the prior year.
  • Change in Cash reached -$4.2 million in Q4 2025 per ARQT's latest filing, up from -$25.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $223.6 million in Q1 2021 and bottomed at -$199.6 million in Q2 2021.
  • Average Change in Cash over 5 years is -$1.2 million, with a median of -$6.2 million recorded in 2022.
  • Peak YoY movement for Change in Cash: crashed 931.49% in 2021, then surged 2045.99% in 2024.
  • A 5-year view of Change in Cash shows it stood at $44.7 million in 2021, then tumbled by 162.46% to -$27.9 million in 2022, then soared by 31.64% to -$19.1 million in 2023, then tumbled by 233.02% to -$63.5 million in 2024, then skyrocketed by 93.37% to -$4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$4.2 million in Q4 2025, -$25.6 million in Q3 2025, and $19.3 million in Q2 2025.